79 related articles for article (PubMed ID: 7909155)
1. The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis.
Ulbright TM; Orazi A; de Riese W; de Riese C; Messemer JE; Foster RS; Donohue JP; Eble JN
Mod Pathol; 1994 Jan; 7(1):64-8. PubMed ID: 7909155
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Orazi A; Ulbright TM; Miller GA; Haidar JH; Donohue JP; Foster RS
Mod Pathol; 1995 Jun; 8(5):492-7. PubMed ID: 7545814
[TBL] [Abstract][Full Text] [Related]
3. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
4. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53.
Oshiro Y; Fukuda T; Tsuneyoshi M
Am J Surg Pathol; 1994 Jul; 18(7):712-9. PubMed ID: 7517104
[TBL] [Abstract][Full Text] [Related]
5. Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma.
Tanioka F; Hiroi M; Yamane T; Hara H
Zentralbl Pathol; 1993 Aug; 139(3):185-93. PubMed ID: 8105885
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.
Heidenreich A; Schenkmann NS; Sesterhenn IA; Mostofi FK; McCarthy WF; Heidenreich B; Moul JW
J Urol; 1997 Aug; 158(2):620-5. PubMed ID: 9224380
[TBL] [Abstract][Full Text] [Related]
7. [Proliferative activity of stage I testicular neoplasms: evaluation by image analysis of immunoreactive MIB-1].
Martinazzi M; Zampieri A; Martinazzi S; Crivelli F; Mauri MF; Calandra C
Pathologica; 1998 Dec; 90(6):783-7. PubMed ID: 10220999
[TBL] [Abstract][Full Text] [Related]
8. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
9. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
Dabbs DJ
Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins.
Eid H; Géczi L; Mágori A; Bodrogi I; Institoris E; Bak M
Anticancer Res; 1998; 18(4C):3059-64. PubMed ID: 9713510
[TBL] [Abstract][Full Text] [Related]
11. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
12. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.
Albers P; Bierhoff E; Neu D; Fimmers R; Wernert N; Müller SC
Cancer; 1997 May; 79(9):1710-6. PubMed ID: 9128986
[TBL] [Abstract][Full Text] [Related]
13. [Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior].
Ji SQ; Hua YW; Zhuang J; Gao Y; Kong Y; Han SL; Shao YF
Ai Zheng; 2002 Jun; 21(6):619-24. PubMed ID: 12452062
[TBL] [Abstract][Full Text] [Related]
14. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
15. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
Mazumdar M; Bacik J; Tickoo SK; Dobrzynski D; Donadio A; Bajorin D; Motzer R; Reuter V; Bosl GJ
J Clin Oncol; 2003 Jul; 21(14):2679-88. PubMed ID: 12860944
[TBL] [Abstract][Full Text] [Related]
16. p53 expression in non small cell lung cancer: clinical and biological correlations.
Fontanini G; Bigini D; Vignati S; Macchiarini P; Pepe S; Angeletti CA; Pingitore R; Squartini F
Anticancer Res; 1993; 13(3):737-42. PubMed ID: 8100413
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis, PCNA and p53 in hepatocellular carcinoma.
Paiva C; Oshima CT; Lanzoni VP; Forones NM
Hepatogastroenterology; 2002; 49(46):1058-61. PubMed ID: 12143201
[TBL] [Abstract][Full Text] [Related]
18. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
20. Correlation of p53 expression and proliferative activity in gastric cancer.
Yonemura Y; Fushida S; Tsugawa K; Ninomiya I; Fonseca L; Yamaguchi A; Miyazaki I; Urano T; Shiku H
Anal Cell Pathol; 1993 Sep; 5(5):277-88. PubMed ID: 8105878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
